Shionogi-Backed Apnimed Files for IPO to Fund Sleep Apnea Drug

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized. Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized. Read the full story on Bloomberg Markets via the link below.